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There is now scientific evidence of genetically driven skin barrier anomalies in atopic 
patients. These barrier anomalies facilitate sustained antigen ingress through the defective 
barrier, which can bring about a Th2-dominant response. It enhances the transepidermal 
water loss, resulting in dry skin and leading to the release of pre-formed pro-inflammatory 
cytokines and to a cascade of events ending up in inflammation. 
There is scientific evidence indicating that skin barrier dysfunction plays a prominent role in 
the development and perpetuation of atopic dermatitis (AD), the “outside-to-inside” view of 
AD pathogenesis.  Moisturizers have a pivotal role in improving and maintaining the skin 
barrier function and in reducing skin susceptibility to irritants.  These emollients are a 
standard of care, the mainstay of AD therapy, and useful for both prevention and maintenance 
therapy.  
Regular use of emollients has a short- and long-term steroid-sparing effect in mild-to-
moderate AD.  They should be recommended in adequate amounts and used liberally and 
frequently in atopic patients.  Recently, “Barrier-repair therapeutics” has entered the market, 
generally as devices, requiring prescriptions (510k-cleared moisturizers). Although this new 
class of moisturizers has shown excellent performance, efficacy, and safety, we could raise 
questions about their superiority over a well-crafted traditional, petrolatum-based OTC 
emollient, as we have been unable to find any scientific evidence to support this claim. In 
addition, there is currently no definition for “barrier-repair products,” raising the additional 




The "outside-to-inside" view of atopic dermatitis and its therapeutic implications 
Until recently, it was thought that the pathogenic mechanism of atopic dermatitis (AD) was 
initiated by immune dysfunction leading to Th1/Th2 cell dysregulation, IgE production, mast 
cell hyperactivity, and dendritic cell signaling. Although both defective epidermal 
permeability that causes dry skin and leads to a predisposition to secondary infection are 
well-recognized features of AD, these conditions have been widely assumed to reflect 
downstream consequences of a primary immunologic abnormality (the historical "inside-to-
outside" view of AD pathogenesis). Accumulating evidence, however, now suggests that a 
primary defect in the stratum corneum may play a key role not only in initiating but also in 
perpetuating AD. This dysfunction of the barrier leads to the release of pre-formed pro-
inflammatory cytokines and sets into motion a cascade of events that provoke and sustain 
disease activity (the "outside-to-inside" view of AD pathogenesis).  
Two main mechanisms account for the outside-to-inside direction of events, that is to say, 
from the impaired barrier to the development of the inflammation. One is the release of a 
cytokine cascade that up-regulates lipid synthesis, lamellar body secretion, and epidermal 
proliferation aimed at the restoration of the barrier function and the initiation of 
inflammation. The other is the penetration of irritants, allergens, haptens, superantigens, and 
bacterial toxins.  
Awareness of the primary role of the stratum corneum in the pathogenesis of AD, as well as 
in other inflammatory diseases, has opened up new therapeutic options and a new therapeutic 
concept: to treat not only the inflammation but also to restore the barrier. The historical 
origins of this concept derive from the numerous, innovative works of Elias and co-workers, 
which have been well presented in a 2001 paper with the catchy title, "Does the tail wag the 
dog?" 
1
 A further step in this direction was the development of a new pharmacologic 
approach aimed at barrier repair. It involves the delivery of balanced proportions of stratum 
corneum-specific lipids to assist in correcting this epidermal barrier dysfunction.  
  
5 
In a state of physiologic balance, the approximate proportions of the lipid component are 
predominantly composed of 50% ceramides, 25% cholesterol, and 10-20% free fatty acids. In 
AD, there is a decrease in all three key lipids, especially ceramides, which are found in both 
affected and non-affected skin. A lipid imbalance and inadequate amounts of ceramides 
contribute to defective formation of the corneocyte lipid envelope and lipid mortar, which 
correlate with increased transepidermal water loss and enhanced barrier permeability 
2
.  
These scientific findings have led to a second look at the use of moisturizers.  
There has been a shift from traditional moisturizers towards ceramide-dominant physiological 
lipid-base barrier-repair topical emulsions. According to several reports 
2
 , these formulations 
focus on physiologic lipid replacement therapy, particularly ceramides, to restore the normal 
balance of the epidermal barrier. Compared with other emollients that form a more superficial 
occlusive barrier (e.g., petrolatum), ceramide-dominant moisturizers are thought to permeate 
the stratum corneum and to be synthesized in the keratinocytes, processed in the lamellar 
bodies, and secreted back into the stratum corneum, where they become a part of the dermal 
matrix.  
In an extensive review by Elias 
3
, the developer of barrier-repair therapeutics, he states:     
“Typical emollient moisturizers, even if they provide some temporary relief through 
moisturization, actually degrade, rather than improve, barrier function, and by providing 
partial relief, they actually delay barrier repair." This, he claims, is in contrast to the use of 
corrective barrier repair creams that contain "sufficient quantities of all three key lipids that 
mediate barrier function (i.e., cholesterol, free fatty acids, and ceramides)…"  
510(k)-cleared prescription moisturizers 
These barrier-repair products to which Elias is referring are technically different from 
traditional over-the-counter (OTC) nonprescription moisturizers, because the Food and Drug 
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Administration (FDA) has approved them as 510(k) devices.  The 510(k) device approval 
process was originally developed to ensure the safety of equipment with an on/off switch.  A 
device that reaches market via the 510(k) process is not considered to be "approved" by the 
FDA, but it can still be marketed and sold in the United States. Such products are generally 
referred to as "cleared" or "510(k)-cleared" devices, where the focus is on safety as opposed 
to efficacy. Although creams are not traditionally thought of as "devices," these topical 
agents have received 510(k) approval, because they induce a physical change in the skin, 
specifically, an increase in skin hydration resulting from a decrease in the transepidermal 
water loss (it is important to note that OTC moisturizers should have exactly the same effect, 
but they have not been registered as devices).  Various formulations that produce barrier 
repair by different mechanisms currently have 510(k) approval as prescription drugs.  
Ceramide-dominant physiological lipid-base barrier-repair products.  
"EpiCeram® Skin Barrier Emulsion" can be considered as the prototype of a ceramide-
dominant physiological lipid-base barrier-repair product. According to Elias’ description, it is 
made up of ceramides, free fatty acids, and cholesterol in what is labeled “optimized 
proportions (i.e., a 3:1:1 molar ratio)”   The product obtained marketing clearance from the 
FDA in April 2006. What is interesting about this moisturizer is that it had originally been an 
OTC product called Triceram® and was subsequently designated as a prescription product 
called Epiceram
®
, with no known changes having been made in its chemical structure.  
Chamlin and colleagues 
4
 published a letter of correspondence entitled “The initial promising 
results of a phase 1 trial of a ceramide-dominant, barrier-repair moisturizer in childhood 
atopic dermatitis.”  The final results of this trial then appeared as an original report  5. This 
modest study was performed on 24 children who continued their prior therapy for stubborn-
to-recalcitrant AD with the only change, being the substitution of their usual moisturizer with 
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the barrier-repair emollient. These authors reported impressive results. The severity scoring 
of AD (SCORAD) values improved significantly in 22 of the children by 3 weeks and in all 
24 of them by 21 weeks. Transepidermal water loss levels (TEWL), which were elevated 
over involved and uninvolved areas at entry, decreased in parallel with SCORAD scores and 
continued to decline even after the SCORAD scores plateaued. In conclusion:  “A ceramide-
dominant, barrier-repair emollient represents a safe, useful adjunct to the treatment of 
childhood AD”.  




 was compared to a mid-
potent steroid (Cutivate
®
 (fluticasone ) ) cream in 121 moderate-to-severe AD patients, aged 
six months to 18 years. EpiCeram® reduced clinical disease severity, decreased pruritus, and 
improved sleeping habits at both 14 and 28 days after initiation of therapy. Although the 
fluticasone-treated group showed significantly greater improvement at 14 days, SCORAD, 
pruritus and sleeping habit scores for EpiCeram did not differ significantly from the 
fluticasone-treated group by 28 days. The conclusion of the authors was: " the ceramide-
dominant, physiological-lipid based formulation could represent an effective stand-alone or 
ancillary therapy for many pediatric patients with AD". What is missing is a study with a 
control group of age-matched pediatric AD patients who were treated solely with OTC 
moisturizers. 
In another 5-center, open-label, interventional study 
7
, a ceramide-dominant, physiologic 
lipid-based emulsion (EpiCeram ®) was evaluated for three weeks either as monotherapy or 
in combination with another AD treatment in 207 patients with mild-to-moderate AD. 
Overall, approximately one-half of the subjects achieved success with investigator global 
assessment (clear or almost clear investigator global assessment scores) after three weeks of 
treatment. A large proportion of subjects (75%) and investigators (for 77% of the subjects) 
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reported satisfaction after three weeks of treatment. Unique to this study was the direct 
involvement of subjects in deciding whether to use an additional treatment in combination 
with the tested moisturizer. The majority of subjects (71%) chose not to add the prescribed 
medication to the ceramide-dominant, physiologic lipid-based product during the three-week 
study period. In conclusion: "…the product was shown to be an effective agent, with or 
without additional topical therapy, to provide good clinical efficacy and high levels of 
investigator and patient satisfaction for many patients with mild-to-moderate AD.”  
The 3-month- to 16-year-old subjects who had been evaluated in the study underwent a 
subgroup analysis 
8
 and the results indicated : "a large percentage of subjects (71%) reported 
satisfaction with clinical results". Again, there was no comparison of the results with a 
matched control group treated with OTC moisturizers.  
Subsequent to the claims that EpiCeram® is in a class of its own as a stand-alone moisturizer, 
being superior, came a paper 
9
 comparing EpiCeram® with another newly developed 
hyaluronic acid-based foam among 30 subjects with mild dermatitis and 30 subjects with 
moderate dermatitis. It was an investigator-blinded and split-body studies in which the 
patients with moderate dermatitis were asked to use additionally a triamcinolone acetonide 
0.1% cream. The authors concluded: "both formulations achieved statistically significant 
improvement in all clinical signs and symptoms of AD by week 4; however, the hyaluronic 
acid foam achieved statistically significant improvement in overall dermatitis severity by 
week 2, whereas the ceramide-containing emulsion cream did not.   Could this indicate that 
there might be a chink in the armor?? 
For the record, there are at least 3 other products approved as 510(k) medical device creams 
that have become available over the past several years and cleared by the FDA for the 
treatment of AD. One of those 3 products is Atopiclair®, a nonsteroidal multicomponent 
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product in which some key ingredients are mixed together with oil in water emulsion. Its 
beneficial effects have been proven in several impressive studies. We found four such 
multicenter, randomized, vehicle-controlled clinical studies that evaluated it. The first 
10
 
comprised 218 adults with mild-to-moderate AD, who administered the test cream or vehicle 
cream 3 times per day to affected areas and those areas prone to be affected. The primary 
endpoint of the study was the score of the Eczema Area and Severity Index (EASI) at day 22. 
The results showed that the cream was statistically more effective than vehicle in all 
outcomes. As could be expected, the authors’ conclusions were: “…the cream is rapidly 
effective and safe as a non-steroidal monotherapy in mild to moderate AD, and it may be 
useful as a topical steroid sparing agent”.  
The third of the four multicenter studies that we found 
12
 was a randomized, double-blind, 
vehicle-controlled trial comprised of 142 patients aged 6 months to 12 years, whose treatment 
consisted of applying either the test substance or the vehicle 3 times per day. The primary 
endpoint for efficacy was the Investigator's Global Assessment (IGA) score for AD at day 22. 
The secondary endpoints were patient/caregiver's assessment of pruritus, onset, duration of 
itch relief, the EASI score, and the need for rescue medication in the event of an AD flare. 
The test substance (Atopiclair®) was found to be significantly more effective (P<. 0001) than 
the vehicle cream for the primary endpoint and for all the secondary endpoints in this cohort 
of infants and children.  
The fourth multicenter double-blind, randomized, vehicle-controlled study on 60 pediatric 
patients
13
 also showed a significant difference between the tested product (Atopiclair®) and 
the vehicle. This study consisted of a treatment period of 43 days. The test substance showed 
80% improvement in the IGA score at day 22, compared with a score of 26.3% for the 
vehicle. This statistical significance was sustained until the end of the study. The authors’ 
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conclusions were that the product “may be considered as one of the available regimens 
effective in the treatment of mild-to-moderate AD in children and adolescents". An OTC 
moisturizer control group was again conspicuously missing.  
 The second prescription device 
 cream, Mimyx®, contains a unique lamellar matrix of pharmaceutical emollient substances, 
including palmitoylethanolamine (PEA). PEA is a cannabinoid agonist that has anti-
inflammatory, antipruritic features and the capacity to inhibit mast cell activation. We are 
aware of at least one very large, multinational, multicenter, non-controlled prospective study 
14
 in which data on the effect of Mimyx® on 2456 patients from 525 centers were analyzed. 
The study showed substantial relief of objective and subjective manifestations of AD.  The 
intensities of  symptoms were reduced (with a combined score reduction of 58% in the entire 
population), previously used topical corticosteroids were discontinued by 56% of all patients, 
and the average weekly application rate decreased by 62%.  
The third prescription topical cream is the lipid-rich Eletone® emulsion. An investigator-
blinded bilateral study 
15
 compared Eletone® emulsion with pimecrolimus cream 1% among 
20 patients with mild to moderate AD. The participants applied pimecrolimus cream twice 
daily to a target lesion on one side of the body and also applied a topical medical device 
cream three times daily on a symmetrical target lesion on the opposite side of the body for 
four weeks. After the 4-week study period, 15 of 20 (75%) sites of both treatments were rated 
"clear" (0) or "almost clear" (1) by the Physician Global Assessment (PGA). Overall, there 
was no statistically significant difference in PGA scores between the treatment sites 
throughout the study (p=0.8236). The authors concluded: "A lipid-rich, non-steroidal, topical 




Prescription moisturizers versus OTC moisturizers 
All of the above-cited studies demonstrated that each tested product is safe and effective in 
treating AD, either as monotherapy or as adjuvant treatment together with other treatments. 
Some of them compared the product to steroids, some to a topical immunomodulator, and 
others to vehicle alone. Even if they achieve the highest marks for objectivity, quality, and 
clinical value, it is impossible for  them to claim that any of the prescription device 
moisturizers are superior to ordinary OTC moisturizers, because none of them compared the 
tested product to an ordinary non-prescription OTC emollient/moisturizer, which is 
inarguably much less expensive.  
There are, however, at least 2 other studies that did compare prescription moisturizers with 
OTC emollients. One of them 
16
 compared a prescription moisturizer (Mimyx®) to a mineral 
oil, petrolatum, and paraffin OTC moisturizer that had been commercially available for over 
100 years. This investigator-blinded research utilized a split-body model in 60 subjects (30 
with mild eczema, 30 with moderate eczema) to examine effect of the two products in the 
treatment of eczema of the arms or legs. The subjects with mild eczema were asked to use the 
OTC moisturizer twice daily to the randomized right or left target limb and a prescription 
device to the other randomized target limb. In addition, 30 subjects with moderate eczema 
were asked to use the OTC moisturizer and 0.1% triamcinolone acetonide cream (TAC) twice 
daily to the randomized limb and a prescription device and TAC. All subjects with mild and 
moderate eczema were rated as being clear by the dermatologist investigator at the end of the 
study. Each target site limb was evaluated separately, and at no time point during the study 
(i.e., at week 1, 2, or 4) were there any statistically significant differences between the OTC 
and device moisturizer. The subject assessments also showed no statistically significant 
differences between the OTC and device moisturizer at any time point. The investigator 
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concluded that parity was established in the treatment of mild-to-moderate eczema with both 
products that showed excellent results.  
The other study that we found 
17
 compared the clinical efficacy of two prescription 
moisturizers and one petrolatum-based skin protectant moisturizer that had been on the 
market for many years as an OTC product (OTC-Pet). Thirty-nine patients aged 2-17 years 
with mild-to-moderate AD were randomized 1:1:1 to receive one of three treatments with 
instructions to apply the treatment, three times daily for three weeks. Evaluations were 
carried out at baseline, day 7, and day 21, and the following were measured: IGA (0-4), body 
surface area (BSA) involvement (0-100), investigator's global assessment of improvement 
(IGAI, 0-6), eczema area and severity index (EASI, 0-72), and a 100 mm visual analog scale 
(VAS) for itch intensity. The final results showed no significant difference for any of the 
measured parameters between the three groups on day 21. OTC-Pet demonstrated no 
significant difference in clinical efficacy from prescription devices moisturizers. The 
demonstration that the clinical success of OTC-Pet is at least as good as the clinical success 
of prescription device moisturizers suggests that the clinical trial results presented by the 
manufacturers of one agent need to be interpreted as representing the performance of that 
single agent in isolation and not as testimony to its superiority over any other prescription 
agents or OTC products.  
What should we recommend to our patients? 
If there is any scientific, evidence-based support for the superiority of the prescription device 
moisturizers over well-crafted, traditional, petrolatum-based OTC emollients, we could not 
find it. The obvious $64,000 question would be, what should we recommend to our patients? 
It seems that this pressing question will have to remain unanswered until more convincing 




Moisturizers for AD: Facts and controversies 
 There is now scientific evidence of genetically driven skin barrier anomalies in atopic 
patients. 
 These barrier anomalies facilitate sustained antigen ingress through the defective 
barrier which can bring about a Th2-dominant response. It enhances the 
transepidermal water loss, resulting in dry skin and leading to the release of pre-
formed pro-inflammatory cytokines and to a cascade of events ending up in 
inflammation. 
 There is scientific evidence indicating that skin barrier dysfunction plays a prominent 
role in the development and perpetuation of AD, the “outside-to-inside” view of AD 
pathogenesis.  
 Moisturizers have a pivotal role in improving and maintaining the skin barrier 
function and reducing skin susceptibility to irritants 
18
.   
 Emollients are a standard of care, the mainstay of AD therapy, and useful for both 
prevention and maintenance therapy 
18
. 
 Regular use of emollients has a short- and long-term steroid-sparing effect in mild-to-
moderate AD.  
 Emollients should be recommended in adequate amounts and used liberally and 
frequently in atopic patients. 
 The type of emollient best suited for this approach has not yet been delineated.  
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 “Barrier-repair therapeutics” has recently entered the market as prescription 510k-
cleared moisturizers.  
 Although this new class of moisturizers has shown excellent performance,  
emphasizing efficacy and safety, there is no evidence to support their superiority over 
a well-crafted traditional, petrolatum-based OTC emollient. 
 There is currently no definition for “barrier-repair products.”   It is unclear,  if 
presently available products justify such a category. The issue is even more cloudy 
with the term “moisturizer,” used for products which do not moisturize. This term was 
actually invented by Madison Avenue marketeers for promoting the simplistic idea 
that moistening the skin will keep it soft and flexible; however, there is currently no 
medical definition of these so called moisturizers or emollients. 
 The approval of emollients , which  do not contain demonstrably active  ingredients 
different from “ordinary” emolients , as prescription devices seems to be a 
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